Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy

Pei Chang Lee, Yu Ju Chen, Yueh Ching Chou, Kuei Chuan Lee, Ping Hsien Chen, Wei Yu Kao, Yi Hsiang Huang, Teh Ia Huo, Han Chieh Lin, Ming Chih Hou, Fa Yauh Lee, Jaw Ching Wu, Chien Wei Su

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The use of nonselective beta blockers in cirrhotic patients experiencing complications is controversial. We aimed to investigate the association between propranolol treatment and outcomes for cirrhotic patients with hepatic encephalopathy. METHODS: Using data from the Taiwan National Health Insurance Research Database, we identified 4754 cirrhotic patients newly diagnosed with hepatic encephalopathy between 2001 and 2010. Among them, 519 patients received propranolol treatment and the other 519 patients without exposure to propranolol were enrolled into our study, both of which were matched by sex, age, and propensity score. The Kaplan-Meier method and time-dependent-modified Cox proportional hazards models were employed for survival and multivariate-stratified analyses. RESULTS: The median overall survival (OS) was significantly longer in the propranolol-treated cohort than in the untreated cohort (3.46 versus 1.88 years, P < 0.001). A dose-dependent increase in survival was observed (median OS: 4.49, 3.29, and 2.46 years in patients treated with propranolol more than 30 , 20-30 , and less than 20 mg/day, respectively [P < 0.001, P = 0.001, and P = 0.079 versus the untreated group]). In addition to reduce the risk of mortality (adjusted hazard ratio, 0.58; P < 0.001), propranolol also diminished the risk of sepsis-related death (adjusted hazard ratio, 0.31; P = 0.006) according to the multivariate analysis. However, the risk of circulatory or hepatic failure was nonsignificantly altered by propranolol treatment. CONCLUSION: Low dose of propranolol treatment was associated with a better OS in cirrhotic patients with hepatic encephalopathy and its effects were dose dependent.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalEuropean journal of gastroenterology & hepatology
Volume32
Issue number3
DOIs
Publication statusPublished - Mar 1 2020

    Fingerprint

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Lee, P. C., Chen, Y. J., Chou, Y. C., Lee, K. C., Chen, P. H., Kao, W. Y., Huang, Y. H., Huo, T. I., Lin, H. C., Hou, M. C., Lee, F. Y., Wu, J. C., & Su, C. W. (2020). Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. European journal of gastroenterology & hepatology, 32(3), 365-372. https://doi.org/10.1097/MEG.0000000000001511